A Goldman Sachs report predicts that the total addressable market for weight loss drugs could reach $100 billion dollars by 2030. Popular weight loss drugs like Novo Nordisk's Ozempic (NVO) have piqued consumers and investors' interest as the drug has called into question its effect on food sales for companies like Walmart (WMT).  Chris Shibutani, Goldman Sachs Pharmaceutical and Biotechnology Analyst, joins Yahoo Finance to discuss how he arrived at the nine-figure evaluation and how companies will have to capitalize on the opportunity. Shibutani outlines some of the challenges drug companies will face going forward: "These are not simple pills and tablets... these are currently frequent injections and they have to be very carefully packaged into syringes, the dose levels are very specific. This is a very carefully developed and designed process that takes quite a bit of sort of manpower as well as manufacturing capacity." For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.

Read more --->